Evidence map›Paper›PMID 39498716›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2025

A Multi-Enzyme Nanocascade to Target Disease-Relevant Metabolites.

Zheng Cao, Jie Ren, Alena Yang, Zi Wang, Maxwell Love, Wenting Chen, Xintong Yuan, Xinheng Guo, Irvin Chen, Yunfeng Lu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zheng CaoDepartment of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Jie RenDepartment of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Alena YangDepartment of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Zi WangDepartment of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Maxwell LoveDepartment of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Wenting ChenDepartment of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Xintong YuanDepartment of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Xinheng GuoDepartment of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Irvin ChenDepartment of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Yunfeng LuDepartment of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Jing WenDepartment of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, 90095, USA.ORCID 0000-0002-6127-6276

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZACK, JEROME A. · 1991 to 2018
$39.9M
In Vivo Gene Editing for HIV-1 CureR01AI145038 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHEN, IRVIN S.Y. · 2019 to 2023
$3.4M
Targeting delivery of mAbs to CNS metastasesR01CA253215 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WEN, JING · 2020 to 2024
$1.7M
An antioxidant enzyme to suppress hyperinflammation induced by SARS-CoV-2R56AI163386 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WEN, JING · 2022 to 2022
$380k
NCATS NIH HHS UL1 TR001881NCATS NIH HHS UL1TR001881NCI NIH HHS R01 CA253215NIAID NIH HHS P30 AI028697NIAID NIH HHS R01 AI145038NIAID NIH HHS R56 AI163386NIH HHS R01AI145038NIH HHS R01CA253215NIH HHS R56AI163386
6 · The paper itself

Abstract

Metabolic processes in living organisms depend on the synergistic actions of enzymes working in proximity and in concert, catalyzing reactions effectively while regulating the formation of metabolites. This enzyme synergy offers promising therapeutic application for diseases such as alcohol intoxication, cancer, and hyperinflammation. Despite their potential, the clinical translation of enzyme cascades is restricted by challenges including poor enzyme stability, short half-life, and a lack of delivery strategies that maintain enzyme proximity. In this study, multi-enzyme nanocascades synthesized are developed through in situ atom transfer radical polymerization using a zwitterionic monomer. This method markedly enhances enzyme stability and proximity, thereby prolonging their circulation half-life after systemic administration. It is demonstrated that the nanocascades of uricase and catalase effectively reduce uric acid levels without excessive hydrogen peroxide production, providing a potential antidote for hyperuricemia. Moreover, in a murine breast cancer model, the nanocascades of glucose oxidase and catalase inhibited tumor progression and enhanced the therapeutic efficacy of doxorubicin. The prolonged circulation and promoted reaction efficacy of these nanocascades underscore their substantial potential in enzyme replacement therapy and the treatment of various diseases.

Indexed as

CatalaseAnimalsCell Line, TumorDoxorubicinFemaleGlucose OxidaseHumansMiceUrate OxidaseUric AcidCatalaseDoxorubicinGlucose OxidaseUrate OxidaseUric Acidcancer starvation therapyenzyme deliverymetabolic reprogrammingprotein nanoparticles

Identifiers

PMID39498716
PMCPMC11750155

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.